Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting

被引:1
|
作者
Kilpelainen, Maritta [1 ,2 ]
Hirvonen, Tuuli [1 ,2 ]
Perkonoja, Katariina [3 ]
Hirsjarvi, Samuli [4 ]
机构
[1] Turku Univ Hosp, Dept Pulm Dis, Turku 20500, Finland
[2] Univ Turku, Turku 20500, Finland
[3] Turku Univ Hosp, Hosp Dist Southwest Finland, Auria Clin Informat, Turku 20521, Finland
[4] Boehringer Ingelheim Finland Ky, Helsinki 00180, Finland
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 02期
关键词
real-world data; interstitial lung disease; idiopathic pulmonary fibrosis; progressive pulmonary fibrosis; incidence; prevalence; IDIOPATHIC PULMONARY-FIBROSIS;
D O I
10.3390/medicina59020281
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: This single-center retrospective study was conducted to describe clinical characteristics and the disease course of patients with interstitial lung diseases (ILD). Materials and Methods: The study included adult patients with fibrosing ILD (IPF, non-IPF fibrosing ILD (F-ILD), and non-IPF progressive pulmonary fibrosis (PPF)) treated between 2014 and 2017. Patients were followed annually from the first visit until the end of the study period in 2019. Data were collected from the Turku University Hospital data lake and analyzed using descriptive statistics. Results: 591 patients formed the patient cohort: 110 had IPF, 194 F-ILD, 142 PPF, and the remaining 145 patients were uncertain, F-ILD-U, whose disease progression nature could not be confirmed by FVC measurements. There were more males in each patient group and median age of the groups was similar, although there were younger patients in the PPF, F-ILD, and F-ILD-U groups. PPF patients had more UIP pattern than F-ILD patients. Exposure-related ILDs were clearly the most found ILD diagnoses for both PPF and F-ILD, followed by unclassifiable IIP. Baseline FVC % predicted reduction in every group was moderate. Half of the patients in each group had comorbidities, and the most common were cardiovascular diseases, diabetes, sleep apnea, and chronic lower respiratory diseases; F-ILD-U patients had malignant diseases as well. IPF patients had less medications than the other groups. Glucocorticoids were the most used medication in all patient groups. More PPF and F-ILD patients remained in the follow-up than IPF and F-ILD-U patients. Similarly, mortality of F-ILD-U was the highest, followed by IPF. Evolvement of lung function, oxygen use, and number of acute hospitalizations were similar for IPF and PPF patients whereas the corresponding results were always better for F-ILD patients. Conclusions: The disease course of IPF and PPF was similar, and PPF patient amount exceeded the amount of IPF patients.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
    Niitsu, Takayuki
    Fukushima, Kiyoharu
    Komukai, Sho
    Takata, So
    Abe, Yuko
    Nii, Takuro
    Kuge, Tomoki
    Iwakoshi, Shinichi
    Shiroyama, Takayuki
    Miyake, Kotaro
    Tujino, Kazuyuki
    Tanizaki, Satoshi
    Iwahori, Kota
    Hirata, Haruhiko
    Miki, Keisuke
    Yanagawa, Masahiro
    Takeuchi, Noriyuki
    Takeda, Yoshito
    Kida, Hiroshi
    Kumanogoh, Atsushi
    [J]. RMD OPEN, 2023, 9 (01):
  • [2] Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
    Dixon, Giles
    Hague, Samuel
    Mulholland, Sarah
    Adamali, Huzaifa
    Khin, Aye Myat Noe
    Thould, Hannah
    Connon, Roisin
    Minnis, Paul
    Murtagh, Eoin
    Khan, Fasihul
    Toor, Sameen
    Lawrence, Alexandra
    Naqvi, Marium
    West, Alex
    Coker, Robina K.
    Ward, Katie
    Yazbeck, Leda
    Hart, Simon
    Garfoot, Theresa
    Newman, Kate
    Rivera-Ortega, Pilar
    Stranks, Lachlan
    Beirne, Paul
    Bradley, Jessica
    Rowan, Catherine
    Agnew, Sarah
    Ahmad, Mahin
    Spencer, Lisa G.
    Aigbirior, Joshua
    Fahim, Ahmed
    Wilson, Andrew M.
    Butcher, Elizabeth
    Chong, Sy Giin
    Saini, Gauri
    Zulfikar, Sabrina
    Chua, Felix
    George, Peter M.
    Kokosi, Maria
    Kouranos, Vasileios
    Molyneaux, Philip
    Renzoni, Elisabetta
    Vitri, Benedetta
    Wells, Athol U.
    Nicol, Lisa M.
    Bianchi, Stephen
    Kular, Raman
    Liu, Hua Jian
    John, Alexander
    Barth, Sarah
    Wickremasinghe, Melissa
    [J]. ERJ OPEN RESEARCH, 2024, 10 (01)
  • [3] PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE IN THE REAL WORLD
    Balzat, L.
    Navaratnam, V
    Godfrey, E.
    Watters, C.
    Reddy, T.
    Bancroft, S.
    Divithotawela, C.
    Godbolt, D.
    Pauli, J.
    Goddard, J.
    Trotter, M.
    Hopkins, P.
    Chambers, D.
    Mackintosh, J.
    [J]. RESPIROLOGY, 2021, 26 : 170 - 170
  • [4] Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease
    Han, Soo Jin
    Kim, Hyeon Hwa
    Hyun, Dong-gon
    Ji, Wonjun
    Choi, Chang-Min
    Lee, Jae Cheol
    Kim, Ho Cheol
    [J]. BMC PULMONARY MEDICINE, 2024, 24 (01)
  • [5] Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease
    Soo Jin Han
    Hyeon Hwa Kim
    Dong-gon Hyun
    Wonjun Ji
    Chang-Min Choi
    Jae Cheol Lee
    Ho Cheol Kim
    [J]. BMC Pulmonary Medicine, 24
  • [6] Clinical course and outcomes of acute exacerbation of fibrosing interstitial lung disease
    Furuta, Katsuyuki
    Fujimoto, Daichi
    Matsunashi, Atsushi
    Tanaka, Masanori
    Shibaki, Ryota
    Shimada, Yuri
    Nagata, Kazuma
    Tomii, Keisuke
    Yamamoto, Nobuyuki
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [7] REAL-WORLD TOLERABILITY STUDY OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE COMPARED TO PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Newman, K.
    Gadoot, T.
    Stranks, L.
    Morris, H.
    Zakis, K.
    Swale, J.
    Greaves, M.
    Stanel, S.
    Ramjug, S.
    Avram, C.
    Blaikley, J.
    Leonard, C.
    Hayton, C.
    Rivera-Ortega, P.
    [J]. THORAX, 2022, 77 : A96 - A96
  • [8] Real-world data from 24 UK centres for the use of nintedanib for progressive fibrosing interstitial lung disease
    Dixon, Giles
    Hague, Samuel
    Mulholland, Sarah
    Khin, Aye Myat Noe
    Thould, Hannah
    Connon, Roisin
    Minnis, Paul
    Murtagh, Eoin
    Khan, Fasihul
    Toor, Sameen
    Lawrence, Alexandra
    Naqvi, Marium
    West, Alex
    Coker, Robina
    Ward, Katie
    Yazbeck, Leda
    Hart, Simon
    Garfoot, Theresa
    Newman, Kate
    Rivera-Ortega, Pilar
    Stranks, Lachlan
    Beirne, Paul
    Bradley, Jessica
    Rowan, Catherine
    Agnew, Sarah
    Ahmad, Mahin
    Spencer, Lisa G.
    Aigbirior, Joshua
    Fahim, Ahmed
    Wilson, Andrew M.
    Butcher, Elizabeth
    Chong, Sy Giin
    Saini, Gauri
    Zulfikar, Sabrina
    Chua, Felix
    George, Peter M.
    Kokosi, Maria
    Kouranos, Vasileios
    Molyneaux, Philip
    Renzoni, Elisabetta
    Vitri, Benedetta
    Wells, Athol U.
    Nicol, Lisa M.
    Bianchi, Stephen
    Kular, Raman
    Liu, Huajian
    John, Alexander
    Barth, Sarah
    Wickremasinghe, Melissa
    Forrest, Ian A.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [9] Real-world appropriateness of imaging severity thresholds in interstitial lung disease clinical trials
    Ryerson, Christopher J.
    Goh, Nicole S. L.
    [J]. LANCET RESPIRATORY MEDICINE, 2020, 8 (02): : E7 - E7
  • [10] Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting
    Assie, J-B.
    Chouaid, C.
    Nunes, H.
    Reynaud, D.
    Gaudin, A-F.
    Grumberg, V.
    Jolivel, R.
    Jouaneton, B.
    Cotte, F-E.
    Duchemann, B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1418 - S1418